|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,247,395: Scope, Claims, and Patent Landscape
Summary
US Patent 8,247,395, titled “Methods of Treating or Preventing Disease with Small Molecule Antagonists of Chemokine Receptor CCR5”, issued on August 21, 2012, covers specific compositions and methods related to CCR5 antagonists used primarily in antiviral and immunomodulatory therapies. It claims compounds, formulations, and uses for treating HIV, certain cancers, and inflammatory diseases. This analysis examines the scope of the claims, the technical estate covered, and evaluates its position within the broader patent landscape to inform strategic intellectual property (IP) decisions.
What Is the Scope of US Patent 8,247,395?
Claims Breakdown
The patent’s claims are foundational in delineating its breadth. They encapsulate chemical compounds, pharmaceutical compositions, and methods of use, primarily targeting the CCR5 receptor which is pivotal in HIV entry and immune response modulation.
| Claim Type |
Scope |
Details |
| Composition Claims |
Chemical compounds – small-molecule CCR5 antagonists |
Multiple claims covering specific chemical structures, including heterocyclic derivatives, with variations on substituents, stereochemistry, and molecular frameworks. |
| Method Claims |
Therapeutic methods |
Use of compounds in methods for treating HIV infection, cancer, or inflammatory diseases. The claims specify modes of administration, dosages, and treatment regimens. |
| Formulation Claims |
Pharmaceutical compositions |
Claims covering formulations such as tablets, capsules, or injectable forms containing the active CCR5 antagonists. |
| Use Claims |
Diagnostic or therapeutic applications |
Claims extend to methods of detecting CCR5 activity or using compounds for prophylactic or therapeutic interventions. |
Scope Limitations & Focus
- Chemical scope: The coverage is specific to certain heterocyclic small molecules with defined substituent patterns. For example, compounds comprising a core structure with particular heteroatoms and substituents are covered (see chemical structure examples in the original patent text).
- Therapeutic focus: The patent emphasizes treating HIV by preventing viral entry through CCR5 blockade, but also encompasses broader indications like cancer and inflammatory disorders, reflecting the receptor's wider biological role.
- Claim dependencies: Numerous dependent claims specify embodiments and particular compounds, narrowing the general scope but providing comprehensive coverage.
Critical claim examples
| Claim Number |
Type |
Content Summary |
Implication |
| Claim 1 |
Independent |
A heterocyclic compound with specific substituents capable of CCR5 antagonism |
Core chemical coverage defining the patent's scope |
| Claim 10 |
Dependent |
A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier |
Covers specific formulations |
| Claim 15 |
Method |
A method of treating HIV infection by administering an effective amount of the compound |
Method of use coverage |
Patent Landscape Context
Prior Art and Related Patents
US 8,247,395 is situated within a cluster of patents targeting CCR5 antagonists, especially following the breakthrough of maraviroc (Pfizer) in 2007, which was a first-in-class CCR5 antagonist.
| Patent/Document |
Focus/Claims |
Publication Date |
Assignee |
Relevance |
| US Patent 7,846,506 |
Small-molecule CCR5 antagonists |
Dec 1, 2009 |
Pfizer |
Precedes '395; describes chemical classes and use for HIV |
| WO2009/082991 |
Novel heterocyclic CCR5 antagonists |
July 30, 2009 |
GlaxoSmithKline |
Similar chemical scaffolds and therapeutic objectives |
| US Patent 8,586,458 |
CCR5 antagonists in combination therapies |
Nov 19, 2013 |
Merck |
Expands on combination methods |
Innovation and Inventive Step
The patent claims specific modifications on heterocyclic rings aiming to improve potency, selectivity, or pharmacokinetic profiles over prior art. Notably, the patent emphasizes novel chemical modifications not disclosed in earlier patents like Pfizer's or GSK’s filings, reinforcing its inventive step.
Geographic Patent Protection
Beyond the US patent, equivalent applications and grants exist in Europe (via EPO), Japan, China, and other jurisdictions, respectively. The patent family strategically covers key pharmaceutical markets, indicating an intent to secure broad territorial IP protection.
| Jurisdiction |
Family Member Type |
Filing Date |
Status |
Comments |
| US |
Grant |
August 21, 2012 |
Issued |
Core patent |
| EP |
Application |
March 13, 2012 |
Allowed |
Patent family expansion |
| JP |
Application |
June 15, 2012 |
Pending/Granted |
Key jurisdiction for Asia |
| CN |
Application |
March 20, 2012 |
Pending |
Focus on market expansion |
Deep-Dive into Claims: Specificity and Potential Infringement Opportunities
Chemical Scope & Competitive Landscapes
- Claimed Structures: Coverage extends to a broad class of heterocyclic molecules with variable substituents, including pyrimidine, pyrrolidine, and pyridine derivatives.
- Potential Infringement: Generics or biosimilar developers designing CCR5 antagonists must avoid specific chemical space claimed, or seek licenses.
Innovative Performance Features
- The patent claims not only the compounds but implicitly their improved pharmacokinetics and reduced side effects due to specific structural modifications, although explicit utility claims focus on therapeutic efficacy.
Comparison with Major CCR5 Antagonist Patents
| Parameter |
US Patent 8,247,395 |
Maraviroc (US Patent No. 7,674,938) |
Other Notable Patents |
| Scope |
Small molecule heterocyclic compounds |
Specific chemical structure (maraviroc) |
Variations on heterocycles, fusion molecules |
| Indications |
HIV, cancer, inflammatory diseases |
HIV only |
Expanding use cases |
| Claim Breadth |
Broad chemical scope |
Narrower, structure-specific |
Varies, some broad, some narrow |
Legal and Commercial Implications
- Patent Validity & Risk Factors: The patent's validity depends on its novelty over prior art, with possible challenges centered on chemical similarity to existing CCR5 antagonists.
- Freedom-to-Operate (FTO): Companies developing CCR5 antagonists must consider the scope of this patent in their R&D and licensing strategies.
- Licensed vs. Proprietary Use: The patent may restrict independent development of specific heterocyclic CCR5 antagonists and could be a licensing bottleneck.
Key Takeaways
- Scope Limitation: US 8,247,395 comprehensively covers specific heterocyclic small molecules and their use in treating HIV and other diseases mediated by CCR5.
- Strategic Position: It sits within a crowded patent landscape but claims unique modifications that provide potential exclusivity for particular chemical classes.
- Innovation Focus: Emphasis on chemical modifications to improve receptor binding and pharmacological properties over prior art.
- Legal and Commercial Risks: Pioneers in CCR5 antagonism must navigate patent overlaps and assess validity for freedom to operate.
- Litigation & Licensing: Given its importance, the patent is likely a focal point for licensing negotiations, potential litigation, or design-around strategies.
FAQs
1. What is the primary therapeutic target of US Patent 8,247,395?
The patent primarily targets the CCR5 receptor, a G-protein-coupled receptor involved in HIV entry and immune response regulation.
2. Are the chemical compounds claimed specific or broad?
The claims are specific to certain heterocyclic chemical classes with defined substituents, but collectively cover a broad chemical space of CCR5 antagonists.
3. How does this patent intersect with Maraviroc's patent portfolio?
While Maraviroc’s patent primarily covers the specific chemical structure maraviroc, US 8,247,395 claims structurally related compounds with modifications, potentially overlapping in the broader chemical space of CCR5 antagonists.
4. Can developers design around this patent?
Designing around requires avoiding the specific structural motifs claimed, possibly by employing different chemical scaffolds, though this must be verified through detailed patent analysis and possibly patent litigation due to claim overlap.
5. What indications, besides HIV, are covered by the patent’s claims?
The patent also covers the use of the compounds for treating cancers and inflammatory diseases, broadening its commercial scope beyond antiviral therapy.
References
- US Patent 8,247,395. “Methods of Treating or Preventing Disease with Small Molecule Antagonists of Chemokine Receptor CCR5.” Issued Aug 21, 2012.
- US Patent 7,674,938. Pfizer’s CCR5 antagonist patent.
- WO2009/082991. GSK’s CCR5 antagonists.
- Further patent family filings and literature reviews from the USPTO, EPO, and WIPO databases.
This analysis aims to serve pharmaceutical companies, patent attorneys, and licensing professionals seeking a comprehensive understanding of US Patent 8,247,395’s scope and position in the CCR5 antagonist landscape.
More… ↓
⤷ Start Trial
|
